BMS 777607

Drug Profile

BMS 777607

Alternative Names: ASLAN-002; BMS-777607; BMS-797669

Latest Information Update: 07 Mar 2017

Price : $50

At a glance

  • Originator Bristol-Myers Squibb
  • Developer ASLAN Pharmaceuticals; Bristol-Myers Squibb; Huntsman Cancer Institute
  • Class Aminopyridines; Antineoplastics; Dihydropyridines; Pyridones; Small molecules
  • Mechanism of Action Proto oncogene protein c met inhibitors; RON protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Breast cancer; Gastric cancer
  • Phase I Osteoporosis
  • No development reported Cancer; Head and neck cancer; Prostate cancer; Renal cell carcinoma

Most Recent Events

  • 07 Mar 2017 No development reported - Phase-II for Head and neck cancer and Renal cell carcinoma (Late-stage disease, Metastatic disease) and Prostate cancer (Late-stage disease, Metastatic disease, Hormone refractory) in Australia (PO, Tablet and Suspension)
  • 20 Feb 2017 Phase-II development is ongoing for Gastric cancer (9212550; 9212551)
  • 20 Feb 2017 Phase-II clinical trials in Breast cancer (PO) before February 2017 (9212550; 9212551)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top